Genzyme’s Campath MS Safety Profile Expected From FDA By July; Phase III Set For Second Half
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm expects to re-start a Phase II trial of alemtusumab in multiple sclerosis patients that was halted in 2005.
You may also be interested in...
Genzyme/Bayer Report Positive Top-Line Phase II MS Data For Campath
Clinical hold on the Phase II trial was lifted “within the last six months” and dosing completed, Genzyme’s Enyedy says.
Genzyme/Bayer Report Positive Top-Line Phase II MS Data For Campath
Clinical hold on the Phase II trial was lifted “within the last six months” and dosing completed, Genzyme’s Enyedy says.
Genzyme Reports Interim Data From Troubled Campath Study
Multiple sclerosis therapy meets efficacy endpoints, but safety issues remain.